IPIX Innovation Pharmaceuticals Inc (CE)

(Check one):

o Form 10-K

o Form 20-F

o Form 11-K

☒ Form 10-Q

o Form 10-D

o Form N-CEN

o Form N-CSR

For Period Ended: December 31, 2020                                           

o Transition Report on Form 10-K

o Transition Report on Form 20-F

o Transition Report on Form 11-K

o Transition Report on Form 10-Q

For the Transition Period Ended: _______________________

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

Innovation Pharmaceuticals Inc.

Full Name of Registrant

N/A

Former Name if Applicable

301 Edgewater Place - Suite 100

Address of Principal Executive Office (Street and Number)

Wakefield, Massachusetts 01880

City, State and Zip Code

(a)

The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

☒

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

(c)

The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

(1)

Name and telephone number of person to contact in regard to this notification

Leo Ehrlich

(978)

921-4125

(Name)

(Area Code)

(Telephone Number)

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes    o No

(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☒ Yes    o No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

The Registrant anticipates reporting net loss for the three and six months ended December 31, 2020 of approximately $6.2 million and $7.3 million, respectively, as compared to $2.6 million and $4.2 million for the three and six months ended December 31, 2019, respectively, largely as a result of increased research and development expense (approximately $3.0 million for the three months ended December 31, 2020 compared to $0.8 million for the three months ended December 31, 2019) and increased interest expense relating to the Registrant’s preferred stock (approximately $2.7 million for the three months ended December 31, 2020 compared to $1.3 million for the three months ended December 31, 2019).